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a b s t r a c t
Transdermal drug delivery is an attractive route of drug administration; however, there are relatively few
marketed transdermal products. To increase delivery across the skin, strategies to enhance skin perme-
ability are widely investigated, with microneedles demonstrating particular promise. Hydrogel-forming
microneedles are inserted into the skin, and following dissolution of a drug loaded reservoir and move-
ment of the drug through the created channels, the microneedle array is removed intact, and can then be
readily and safely discarded. This study presents the formulation and evaluation of an integrated micro-
needle patch containing the Alzheimer’s drug, donepezil hydrochloride. The integrated patch consisted of
hydrogel-forming microneedles in combination with a donepezil hydrochloride containing film.
Formulation and characterisation of plasticised films, prepared from poly(vinylpyrrolidone) or poly
(methyl vinyl ether co-maleic anhydride/acid) (Gantrez) polymers, is presented. Furthermore, in vitro
permeation of donepezil hydrochloride across neonatal porcine skin from the patches was investigated,
with 854.71 lg ± 122.71 lg donepezil hydrochloride delivered after 24 h, using the optimum patch for-
mulation. Following administration of the patch to an animal model, plasma concentrations of
51.8 ± 17.6 ng/mL were obtained, demonstrating the success of this delivery platform for donepezil
hydrochloride.
 2016 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Microneedles (MNs)1 are minimally invasive devices capable of
penetrating the skin’s stratum corneum, overcoming its barrier prop-
erties. This increases the potential for transdermal delivery of a
greater number of drugs, as the prerequisite for substances to have
specific physicochemical properties for passive transdermal delivery
is negated [1]. Transdermal drug delivery has numerous well docu-
mented benefits, including avoidance of first-pass hepatic metabo-
lism, the offer of controlled drug delivery, and reduction in
gastrointestinal side-effects and is particularly useful for patients
with dysphagia [2]. Since description of the first studies exploring
the delivery capabilities of MNs, interest in the field has grown expo-
nentially [3–5]. It has been acknowledged, that of the various strate-
gies to enhance transdermal drug delivery, MN technology is
progressing with the greatest promise, with human studies already
conducted for the delivery of vaccines via this mechanism [6].
The various MN types have been extensively discussed, with the
benefits and limitations of each type identified [7,8]. Hydrogel-
forming MNs have several unique characteristics which make
them suitable for a broad range of drug delivery applications. They
are hard in the dry state, enabling successful insertion into the
skin. Once in situ, they imbibe interstitial fluid and swell. This cre-
ates a porous network through which drug contained within a
reservoir can diffuse from, and move into the dermal microcircula-
tion (Fig. 1) [9]. Modification of MN swelling confers the ability to
control rate of drug release. The drug reservoir is formulated inde-
pendently of the MNs allowing further manipulation of the drug
delivery system and, as a result, drug loading is not restricted to
what can be contained within the needles themselves; a distinct
advantage in comparison with dissolving and coated MNs. Aside
from MN studies involving the delivery of a vaccine, the majority
of drugs used have been for exemplar purposes. As the field contin-
ues to progress, the question as to what other applications MNs
may have, has been asked [10].
The benefit of transdermal products in Alzheimer’s disease has
been recognised with a rivastigmine patch currently on the market.
This product had an excess of US $400 million in sales in 2014,
highlighting the commercial success of transdermal products for
patients suffering from this condition [11]. Anti-Alzheimer’s drugs
http://dx.doi.org/10.1016/j.ejpb.2016.03.026
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are therefore a logical therapeutic choice when considering a clin-
ically useful MN product. Donepezil (Fig. 2) (2-[(1-benzylpiperidin-
4-yl)methyl]-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one) is an
acetylcholinesterase inhibitor used in the treatment of mild to
moderate dementia in Alzheimer’s disease. Alzheimer’s disease is
the most prevalent form of dementia, which affects 835,000 people
in the UK. With an ageing population and improved diagnoses, the
number of people suffering from this condition, in the UK, is pre-
dicted to increase to over 2 million by 2051 [12]. Alzheimer’s dis-
ease is associated with a reduction in certain cerebral
neurotransmitters, including acetylcholine. The aim of donepezil
treatment is to inhibit the hydrolysis of acetylcholine, thereby
increasing its concentration in the synaptic cleft, and consequently,
improving neurotransmission. It has been hypothesised that done-
pezil formulated as a transdermal patch, similar to rivastigmine,
could provide significant patient benefit. A particular advantage
of avoiding the gastrointestinal (GI) tract, by using a patch formu-
lation, is a reduction in GI related side effects. Further to this, dys-
phagia is a common symptom of Alzheimer’s disease, frequently
hindering treatment with oral preparations [11]. Poor compliance
to medication regimens amongst patients suffering from Alzhei-
mer’s disease is commonly reported, with one study finding that,
following six months of oral donepezil treatment, only 52% of
patients were fully adherent [12]. It has been shown that compli-
ance in the elderly population is greater with transdermal patches
in comparison with the oral form [13,14].
The base form of donepezil has a Log P of 3.08–4.11 and does
not passively traverse the skin at clinically relevant levels
[15,16]. To enhance transdermal delivery, various methods have
been employed, mainly penetration enhancers [16,17] and ion-
tophoresis [18]. These methods have investigated the delivery of
both the free base form of the drug and the hydrochloride (HCl)
salt. As it has been demonstrated that MNs can significantly
increase the transdermal delivery of small, water soluble drug sub-
stances, we hypothesise that MNs could be used to facilitate the
transdermal delivery of donepezil HCl (molecular weight:
433.97 g/mol). Our previous work has largely focused on the deliv-
ery of compounds with representative physicochemical properties
using this novel MN system [9]. In contrast this study examines the
modification and development, of this delivery system for a thera-
peutically relevant compound. The aim of the current study was to
develop a novel ‘integrated’ MN patch consisting of a donepezil HCl
loaded film and hydrogel-forming MNs for enhanced in vitro and
in vivo transdermal delivery of this Alzheimer’s drug.
2. Materials and methods
2.1. Materials
Gantrez AN-139 and S-97, copolymers of methyl vinyl ether
and maleic anhydride and methyl vinyl ether and maleic acid,
respectively (PMVE/MAH and PMVE/MA, with molecular masses
of 1,080,000 and 1,500,000 respectively) were gifts from Ashland,
Kidderminster, UK. Poly(ethylene glycol) (PEG MW 10,000 Da),
poly(vinylpyrrolidone) (PVP, MW 58,000 g/mol), glycerol, tripropy-
lene glycol methyl ether (TPME), triethylamine and HPLC grade
methanol and acetonitrile were purchased from Sigma Aldrich,
Dorset, UK. Donepezil HCl was purchased from TCI UK Ltd., Zwijn-
drecht, Belgium. All other chemicals used were of analytical
reagent grade.
2.2. Fabrication of hydrogel-forming MNs
MN arrays were fabricated from aqueous blends containing 15%
w/w Gantrez S-97, 7.5% w/w PEG, 10,000 and 3% w/w Na2CO3 as
previously described [19]. Approximately 500 mg of blend was
poured into 11  11 MN moulds and these were centrifuged at
2205 g for 15 min and dried at room temperature for 48 h.
Crosslinking was induced via an esterification reaction, by heating
the MNs at 80C for 24 h [20]. Following this 24 h heating process,
moulds were allowed to cool and the arrays extracted, with side-
walls formed by the moulding process removed using a heated
blade. The final arrays produced contained 121 needles perpendic-
ular to the base and of conical shape (600 lm in height, with base
width of 300 lm and 150 lm interspacing on a 0.49 cm2 patch).
2.3. Pharmaceutical analysis of donepezil hydrochloride
To analyse donepezil HCl delivered in vitro, a reverse phase high
performance liquid chromatography (RP-HPLC) method was devel-
oped. An Agilent 1200 series system (Agilent Technologies UK Ltd.,
Stockport, UK) was used for analysis. The column used was a Phe-
nomenex Luna C18 (ODS1) column (150 mm  4.6 mm internal
diameter, 5 lm packing, Phenomenex, Cheshire, UK) with UV
detection at 272 nm (run time per sample = 6 min). The mobile
phase consisted of 65:34.5:0.5 acetonitrile:0.025 M potassium
dihydrogen phosphate buffer (pH 3.0):triethylamine, at a flow rate
of 1 mL/min. Column temperature was maintained at 25C and
injection volume was 20 lL. Agilent ChemStation Software
B.02.01 was used for chromatogram analysis. Correlation analysis
along with least squares linear regression analysis was performed
on the calibration curves generated, enabling determination of the
equations of the line and their coefficients of determination. Limits
Fig. 1. Schematic representation of the mechanism of action of hydrogel-forming MNs in combination with a drug loaded reservoir.
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Fig. 2. Molecular structure of donepezil.
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of detection (LoD) and limits of quantification (LoQ) were deter-
mined using a method based on the standard deviation of the
response and the slope of the representative calibration curve, as
described in the guidelines from ICH [21]. The LoD of each method
was determined as follows, using Eq. (1):
LoD ¼ 3:3r
S
ð1Þ
where r is the standard deviation of the response data used to con-
struct the regression line and S is the slope of that line. Similarly,
the LoQ was determined using Eq. (2):
LoQ ¼ 10r
S
ð2Þ
For analysis of donepezil HCl in plasma samples, the above RP-
HPLC method was optimised to facilitate donepezil HCl detection
at lower concentrations. A WatersTM XSelect CSH C18 column
(75 mm  3 mm internal diameter, 2.5 lm packing) was used for
the separation with fluorescence detection at k excitation
318 nm and k emission 390 (run time = 5 min). The mobile phase
consisted of 30:70 acetonitrile:0.025 M potassium dihydrogen
phosphate buffer (pH 3.0) at a flow rate of 0.7 mL/min. The injec-
tion volume was 10 lL. Agilent ChemStation Software B.02.01
was used for chromatogram analysis.
2.4. Preparation of donepezil HCl loaded films
Donepezil HCl containing films were prepared by using a cast-
ing method, from aqueous blends of PMVE/MAH, PMVE/MA or
PVP polymers and a plasticiser, as detailed in Table 1. Required
amounts of donepezil HCl were added directly into the aqueous
blends. An aliquot of drug loaded aqueous blend was cast in either
a silicone mould (5 cm  5 cm) or a mould consisting of a stainless
steel frame secured on a Perspex base (5 cm  2 cm). The mould
was placed on a levelled surface, allowing even spreading of the
formulation. The cast blend was then dried at room temperature
for 48 h.
2.5. Physical characterisation of donepezil HCl containing films
Film thickness was measured using a digital micrometer (Hilka,
ProCraft, Surrey, UK) and a TA-XT2 Texture Analyser (Stable
Microsystems, Haslemere, UK) was used for determination of ten-
sile strength, percentage elongation and calculation of Young’s
Modulus. Film strips (50 mm  5 mm) were secured between
two grips set at 20 mm spacing and a cross-head speed of
0.5 mm/s was used.
2.6. Donepezil HCl film recovery
Segments (1 cm2) of donepezil HCl-containing films were dis-
solved in 100 mL of PBS stirred at 400 rpm at 37C. Following dis-
solution, samples were diluted appropriately and filtered using
0.22 lm Millex-GS syringe filter (Merck Millipore Ltd., Carrigt-
wohill, Ireland) and analysed using the RP-HPLC with UV detection
method, as outlined above.
2.7. Donepezil-containing films dissolution study
Films measuring 1 cm2 were weighed, immersed in 30 mL PBS
(pH 7.4) and removed at pre-defined time-intervals. Upon removal,
excess PBS was removed by blotting with filter paper and samples
reweighed until the point of complete film dissolution.
2.8. In vitro donepezil drug delivery studies
Modified Franz cell chamber system was used to assess the per-
meation of donepezil HCl from films in combination with
hydrogel-forming MNs, across dermatomed, neonatal porcine skin
(Fig. 3). Skin samples were obtained from stillborn piglets and
immediately (<24 h after birth) excised, trimmed to a desired
thickness (approximately 350 lm) using an electric dermatome
(Integra Life SciencesTM, Padgett Instruments, NJ, USA) and frozen
at 20C until use. MN arrays (11  11 needle density, 600 lm
height, 300 lm width at base and 150 lm interspacing) were
inserted using manual pressure with 20 lL PBS placed on the array
to promote adhesion of the films containing approximately 2 mg
donepezil HCl to the MN baseplate. A cylindrical 5.0 g stainless
steel weight was placed on top of the MN array to prevent MN
expulsion, and the donor compartment of the apparatus was
clamped onto the receiver compartment. The donor compartment
and sampling arm were sealed using Parafilm M. The receiver
compartment contained PBS (pH 7.4) degassed prior to use and
thermostated to 37 ± 1C. Syringes (1.0 mL) with 8.0 cm needles
were used to remove 200 lL of the Franz cell contents at
pre-determined time intervals and 200 lL of pre-warmed PBS
was subsequently added to replace this. Control Franz cells were
assembled in the same manner, but without the application of
MN arrays. Instead, the drug loaded films were applied directly
to the skin.
2.9. In vivo drug delivery studies
Male Sprague–Dawley rats weighing 260.8 ± 13 g, were allowed
to acclimatise for 7 days prior to experimentation. To minimise
interference of rat hair with MN application, it was removed from
the back region 24 h prior to the experiment. Firstly, an animal hair
clipper was used to remove the bulk of hair with depilatory cream
(Boots Expert The Boots Company PLC, Nottingham, UK) then
applied to remove any residual hair. Following this, there was a
24 h recovery period to ensure complete restoration of skin barrier
function [9,22]. To facilitate MN application, rats were anesthetised
using gas anaesthesia (2–4% isoflurane in oxygen). Rat skin was
pinched and four MN arrays, mounted on an adhesive foam border
(TG Eakin Ltd., Comber, Co Down, UK), were inserted into the backs
of each rat using firm finger pressure. Donepezil HCl-loaded films
(F1) with a drug loading of either 5 mg/kg or 2.5 mg/kg were
applied to the back of the arrays covering the area exposed to
the MNs. To secure the integrated patch in place, an occlusive
transdermal backing consisting of Duro-tak adhesive grade 387-
2054 and ScotchpakTM film (3 M UK Plc, Bracknell, Berkshire, UK)
was applied on top of the arrays and this was further wrapped in
place using Micropore tape (3M UK Plc, Bracknell, Berkshire,
UK). Blood samples were taken via tail vein bleeds at pre-defined
time intervals: 1, 2, 4, 6 and 24 h with a maximum of 200 lL col-
lected at each sampling point. These samples were processed as
Table 1
Formulations for donepezil containing films.
Formulation % w/w
Gantrez
AN 139
% w/w
Gantrez
S97
% w/w
PVP
K29/32
% w/
w
TPM
% w/w
PEG
400
% w/w
Glycerol
F1 15 – – 7.5 – –
F2 – – 15 – 5 –
F3 – – 15 – – 5
F4 – 10 – 5 – –
F5 – 15 – 7.5 – –
F6 10 – – 5 – –
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detailed below prior to RP-HPLC analysis. Approval for animal
experiments was obtained from the Committee of the Biological
Research Unit, Queen’s University Belfast. The work was carried
out under the Project Licence PPL 2678 and the Personal Licence
PIL 1465. All in vivo experiments were conducted according to
the policy of the federation of European Laboratory Animal Science
Associations and the European Convention for the protection of
vertebrate animals used for experimental and other scientific pur-
poses, with implementation of the principles of the 3R’s.
2.10. Extraction of plasma and drug
Healthy male Sprague–Dawley rats were culled and blood was
collected into heparinised tubes following cardiac puncture. This
control blood was used for assay method development. To separate
plasma from the blood, the tubes were centrifuged at 3000 relative
centrifugal force (RCF) for 10 min at 4C. 180 lL of plasma was sub-
sequently aliquoted into 1.5 mL Eppendorf tubes and stored at
80C until used. Aliquots (20 lL) of donepezil HCl working stan-
dard solutions were added to 180 lL blank plasma and vortexed
for 10 s. Acetonitrile (500 lL) was then added to the plasma/stan-
dard mixture and vortex-mixed for 10 min. This was followed by
centrifugation at 14,000 RCF for 10 min at 4C. The supernatant
was removed from the Eppendorf tube and transferred to a dis-
posable glass culture tube. The acetonitrile extraction procedure
was repeated to ensure optimum extraction of donepezil HCl with
the supernatant again transferred to the culture tube. The sample
extract was then dried under a stream of nitrogen at 35C for
50 min using a Zymark TurboVap LV Evaporator Workstation
(McKinley Scientific, Sparta, NJ, USA). The residue was then recon-
stituted in 200 lL PBS (pH 7.4) and collected into an Eppendorf.
This was vortex-mixed for 30 s and centrifuged at 14,000 RCF for
10 min at room temperature. The supernatant was transferred into
an Agilent HPLC vial and 10 lL was injected onto the HPLC
column.
2.11. Statistical analysis
A One-way ANOVA test was used to compare the various film
formulations in terms of strength, elongation and donepezil HCl
recovery. Where appropriate, an unpaired t-test or Mann–Whitney
U test was used to statistically compare the results of in vitro data
and in vivo data. In all cases, p < 0.05 denoted significance. Statisti-
cal analysis was carried out using GraphPad Prism version 5.0
(GraphPad Software Inc., San Diego, California).
3. Results
3.1. Pharmaceutical analysis of donepezil hydrochloride
HPLC methods for the quantification of donepezil HCl, in either
PBS or plasma, were developed and validated according to ICH
guidelines. Limits of quantification and detection are presented
in Table 2 (i) and (ii) respectively. Typical HPLC traces for each
method are displayed in Fig. 4a and b.
3.2. Physical characterisation of donepezil HCl containing films
Donepezil HCl containing films were characterised in terms of
dimension uniformity, tensile strength, percentage elongation
and Young’s modulus. Details of the film formulations are docu-
mented in Table 1. All films were of similar thickness with an aver-
age thickness of 0.41 mm ± 0.05 mm. No significant difference was
found between any of the formulations apart from F6, which dis-
played higher tensile strength (p < 0.05) (Fig. 5a) and much less
elasticity (p < 0.05), as determined by % elongation, (Fig. 5b) in
comparison with the other formulations.
3.3. Donepezil HCl film recovery
Films containing a known mass of donepezil HCl were dissolved
in PBS and the concentration of the drug contained within was
Fig. 3. Schematic representation of modified Franz cell chamber system for in vitro testing of donepezil HCl permeation across neonatal porcine skin using hydrogel-forming
MNs.
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determined. Recovery of donepezil HCl from F6 was not assessed as
mechanical properties of this formulation were deemed not suit-
able for this application. Recovery from all investigated films was
over 90% with an average recovery of 96.96% ± 6.56% (Fig. 5c). This
suggests that there were no meaningful compatibility issues
between the drug and film components.
3.4. Donepezil-containing films dissolution study
Films were dissolved in PBS to determine an estimated dissolu-
tion rate. Films based on PMVE/MAH and PMVE/MA were found to
initially swell with subsequent dissolution. Contrastingly, films
composed of PVP dissolved rapidly, with complete dissolution hav-
ing occurred within 15 min, almost 4-times faster than PVME/MA
and PVME/MAH films. Complete film dissolution for all formula-
tions occurred within 40 min of immersion into PBS (Fig. 5d).
3.5. In vitro donepezil drug delivery studies
Permeation of donepezil HCl across neonatal porcine skin was
significantly enhanced by using MN arrays in comparison with
the control set-up (p < 0.05). The composition of the donepezil
HCl film reservoir impacts on the total permeation. Following
application of the combined MN and film formed from F1 for
24 h, 854.71 lg ± 122.71 lg donepezil HCl was delivered, in com-
parison with 266.81 lg ± 172.68 lg delivered from the patch con-
taining a PVP based film (F3). Permeation from films prepared from
four of the six test formulations was investigated; however data
presented include permeation from F1 and F3. These are presented
as these represent the maximum delivery of donepezil HCl from a
Gantrez based film and a PVP based film. Permeation from the
other films was lower and these formulations were therefore not
considered for the in vivo study. F4 was not investigated at this
stage as donepezil HCl recovery was 90.2% ± 4.2%. As stated previ-
ously, F6 was not tested after considering the results of its physical
properties. F1 The permeation rate of donepezil HCl was calculated
using Eq. (3) from the slopes of the linear portions of the perme-
ation profiles.
Permeation rate ¼ dM
S dt ð3Þ
where M is the mass of donepezil HCl permeated through the
MNs, of unit cross-sectional area (S) in unit time (t). For the Gan-
trez based integrated patch, the permeation rate was 172.2 lg/
h/cm2 ± 34.9 lg/h/cm2 between 2 and 6 h and 269.9 lg/h/
cm2 ± 105.4 lg/h/cm2 between 1 and 4 h for the PVP based inte-
grated patch. Although the permeation rate is higher for the PVP
based patch over the linear period, following this the permeation
of donepezil HCl rapidly plateaus (after 4 h), with significantly less
permeated from this system by 24 h (p < 0.05). It is noticeable that
the error associated with the permeation rate of the PVP based film
is considerably large and error is often reported with the use of
biological membranes such as porcine skin [23]. Further to this,
it is acknowledged that the permeation rates calculated are an
approximation, as, with hydrogel MNs the area of the array
increases as the system swells; this too may potentially contribute
to error. In terms of percentage delivery, after 24 h 34.63% ± 3.70%
of donepezil HCl contained within the Gantrez based patches was
delivered in comparison with 13.11% ± 4.83% from PVP based films.
When compared to the control setup, both MN patches demon-
strated enhanced delivery (p < 0.05) (Fig. 6).
3.6. In vivo drug delivery and quantification
Each rat had a total of four integrated MN patches applied to
their back with three rats administered 2.5 mg/kg donepezil HCl,
and three administered 5 mg/kg donepezil HCl. As can be seen
from the plasma profile (Fig. 7a) donepezil HCl was detected in
the rat plasma after 1 h at a concentration of 28.2 ng/mL and
32.0 ng/mL for the 2.5 mg/kg and 5 mg/kg doses respectively. Con-
centrations progressively increased over the 24 h experiment dura-
tion, with a maximal concentration of 51.8 ± 17.6 ng/mL achieved
for the higher drug loading and 35.6 ± 13.0 ng/mL for the lower
loading at 24 h. The higher concentration achieved with the
increased drug loading was not found to be statically different in
comparison with the lower concentration (p > 0.05). Pharmacoki-
netic parameters are presented in Table 3. Css was calculated using
Eq. (4), where AUC is the area under the curve and t is time.
Css ¼ AUC0t
t
ð4Þ
Interestingly, Tmax (Time of Maximum concentration
observed) was 24 h in both rat cohorts. This may lead to a slight
discrepancy of Css (steady state plasma concentration), as true
steady state conditions cannot be claimed after this time period
as the plasma concentrations at this time point had not plateaued.
As can be seen from Fig. 7b, after 24 h the MN arrays had swollen
extensively with dissolution of the donepezil HCl containing film.
Table 2
Calibration curve properties for donepezil HCl quantification in (i) PBS (pH 7.4) and
(ii) rat plasma and limits of detection and quantification for donepezil HCl.
Slope y-Intercept r2 LoD (lg/mL) LoQ (lg/mL)
9.3854 0.7042 0.9999 0.11 0.52
329 0.0426 0.9959 0.01 0.03
Fig. 4. Typical HPLC traces of donepezil HCl in (a) PBS and (b) rat plasma.
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4. Discussion
The benefit of transdermal products for use in older populations
and those affected by dementia has been well documented and
confirmed by commercial success of the rivastigmine patch. Pre-
sented in this paper is the novel combination of a donepezil HCl
containing film with hydrogel-forming MNs for the enhanced
transdermal delivery of this Alzheimer’s drug. Hydrogel-forming
MNs have been shown to increase the transdermal delivery of a
range of model therapeutic compounds with a diverse range of
physicochemical properties [9,19,24]. This highlights the versatil-
ity of this MN design and, coupled with their self-disabling nature,
hydrogel-forming MNs show considerable promise for commercial
success.
When inserted into the skin, hydrogel-forming MNs swell and
create a porous, aqueous network through which drug substances
can diffuse through, and reach the rich dermal microcirculation
below. Due to the aqueous environment created by these MNs,
Fig. 5. Physical characterisation of donepezil HCl containing films made from formulations F1–F6: (a) tensile strength of films (means ± SD, n = 5), (b) percentage elongation
at break of films (means ± SD, n = 5), (c) dissolution profile of films in PBS (7.4 pH at 25C) (means ± SD, n = 3) and (d) recovery of donepezil HCl from films after dissolving in
PBS and detected using RP-HPLC (means ± SD, n = 3).
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Fig. 6. In vitro cumulative permeation profile of donepezil HCl, across dermatomed
neonatal porcine skin, from integrated patches composed of hydrogel forming MNs,
and either a PVP or a PMVE/MAH-based drug loaded film (means ± SD, n = 3).
Fig. 7. (a) The in vivo plasma profiles of donepezil HCl (means ± SD, n = 3) following transdermal delivery from MN integrated patches at a dose of either 5 mg/kg or 2.5 mg/
kg. (b) Digital photograph of MN array applied to the back of a rat after 24 h, with adhesive backing removed.
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delivery is most suited to drugs with a relatively high degree of
water solubility. For this reason the HCl salt version of donepezil
has been used in this study, which is in contrast to other
approaches to the development of a donepezil patch, which have
used the free base form [17].
The polymers selected for film preparation to be used in combi-
nation with MNs, to form an integrated patch in this study, have
been previously shown to have film-forming properties [20,25].
They are biocompatible, having been used extensively in the phar-
maceutical industry. These materials are water soluble and are,
therefore, logical choices of polymers for this study. PVME/MAH
has previously been used in combination with hydrogel-forming
MNs for the delivery of the model compounds methylene blue,
metronidazole and theophylline. As progression towards a com-
mercial product continues [26], there is increasing preference for
the use of the benzene free PVME/MA polymer, and as a result both
were investigated [27]. With the view of modifying the release
kinetics of the integrated patch, films composed of PVP with a con-
siderably lower molecular weight than the other polymers were
investigated. The mechanism of drug release from the integrated
patch is diffusion; therefore, it was hypothesised that a film formed
from a lower molecular weight would diffuse more rapidly than its
higher molecular weight counterparts. PVP based films were there-
fore tested in combination with the hydrogel-forming MNs, as well
as Gantrez based films, in terms of donepezil HCl permeation.
Characterisation of the films physical properties was conducted
to assess the suitability of the formulation for use in a transdermal
application. The film requires a certain degree of flexibility to
enable sufficient contortion to be applied to the skin, but also suf-
ficient strength to facilitate ease of handling. Previous work has
investigated the effects of various plasticisers on the physical char-
acteristics of PMVE/MAH based films and concluded that the opti-
mum plasticiser in films for transdermal applications is TPME [20].
Reducing the TPME concentration from 7.5% to 5% of PMVE/MAH
based films significantly reduced their flexibility. It has been
hypothesised that water also contributes to the plasticising effect
of films containing TPME and, as the film dries upon storage the
flexibility is reduced. Using the films immediately post-
formulation would circumvent this, but would not make a suitable
pharmaceutical product as inevitably a storage period prior to use
will be necessary. To overcome this issue, heat-sealed, moisture-
impermeable packaging has been used and found to be a suitable
remedy [20].
In vitro permeation of donepezil HCl was assessed using the
commonly employed Franz cell apparatus. A 1 cm2 patch contain-
ing approximately 2 mg donepezil HCl delivered almost 1 mg
donepezil from the integrated patch composed of hydrogel-
forming MNs and F1. While it is acknowledged that porcine skin
is not an exact model of human skin, it is a close replicate in terms
of stratum corneum thickness and hair distribution [25]. As the pri-
mary barrier to transdermal delivery is the stratum corneum, por-
cine skin is therefore a suitable model membrane. Previously we
have shown that the optimum skin model in terms of in vitro to
in vivo was dermatomed porcine skin (thickness of 350 lm) using
MNs with a height of 600 lm [25]. The integrated patch was
applied to the skin with gentle pressure exerted to ensure insertion
of MN tips. Following insertion, the MNs take up interstitial fluid
with subsequent swelling and expansion of the hydrogel matrix,
facilitating movement of molecules through the channels created
in the skin. The imbibed fluid causes dissolution of the film atop
the MNs with the donepezil contained within diffusing through
the MNs and into the receiver compartment below. Patches con-
taining PVP based films had significantly less permeation in com-
parison with Gantrez based films (p < 0.05). While results of
dissolution studies suggested that PVP based films dissolve more
rapidly, in terms of an integrated patch, it is the rate of MN swel-
ling that has greater influence on the dissolution of the films, as the
needles must initially swell before the patch dissolves. Despite the
higher flux values over the linear portions of the permeation pro-
file for the PVP based patches, after 24 h this system did not deliver
the largest amount of donepezil HCl. In fact, after 5 h, delivery from
PVP-based integrated patches reached a plateau, suggesting that
this system would not be suitable for a 24 h patch. Upon visual
inspection of the Franz cell donor compartment post experiment,
it was obvious that there was complete dissolution of the PVP-
based films, yet a significantly less amount of donepezil HCl was
delivered in comparison with the Gantrez-based films (p < 0.05).
This may possibly be attributed to the formation of hydrogen
bonds between the carbonyl groups of PVP and hydroxyl groups
of the PMVE/MA MNs, causing a reduction in the solubility of
PVP when passing through the MNs due to reduced interaction
with water molecules and potential complexation with the MN
matrix itself [28].
The in vivo animal study has demonstrated that hydrogel-
forming MNs can be used to deliver a clinically relevant drug, at
therapeutically useful doses, in comparison with the many studies
that investigate model compounds, offering potential for the cur-
rent transdermal drug delivery market. Donepezil HCl delivered
from an integrated MN patch yielded plasma concentrations in
the rat model similar to the target therapeutic concentration in
humans [29]. While it is acknowledged that the pharmacokinetics
of a rat and a human are quite disparate, the preliminary results of
this small scale study are very encouraging. When cautiously
extrapolated, a human donepezil HCl dose of 5 mg/kg could be
achieved with a patch size of approximately 30 cm2. Considering
an average human mass of 60 kg, it is possible to load 160 mg
donepezil HCl in 9 g formulation (9 g formulation is used to pro-
duce a film of an average thickness of 0.7 mm and area of
15 cm2). Although it is recognised that the dose of donepezil HCl
used in this experiment is much higher than the oral human dose,
the numerous advantages offered by a patch formulation of done-
pezil make these endeavours worthwhile. Considering the delivery
profile of donepezil HCl, it is notable that steady state conditions
were not reached within the duration of this experiment. Saluja
et al. have reported similar results with transdermal delivery of
donepezil HCl using iontophoresis, where an average Tmax of
25.5 h was observed [18]. It is assumed that the rate of absorption
is slower with transdermal delivery, and similarly there is a lag
time with MN patches, as the MNs must take up interstitial fluid,
the drug-loaded film dissolves, and then the drug must diffuse
through the MN hydrogel matrix, prior to partition into the dermal
microcirculatory system. Once the drug has diffused through the
MNs, however, uptake by the dermal microcirculation is rapid
[30]. With an extension of the experimental run time it would be
predicted that constant plasma concentrations of donepezil would
be maintained, as the MNs had reached a state of maximum swel-
ling at 24 h, and the donepezil would move through the swollen
MNs and be taken up by the rich dermal microcirculation until
depletion of the reservoir patch and diffusion through the array.
The duration of the in vivo study was kept to a minimum due to
a restriction in blood sampling volumes within a given time period,
as well as considering the aim of the study, which was to establish
Table 3
Pharmacokinetic parameters of donepezil applied to rats at a dose of 3 mg/Rat or
1.5 mg/Rat (means ± SD, n = 3).
Parameter 5 mg/kg 2.5 mg/kg
AUC (ng h/mL) 894.5 ± 128.3 702.3 ± 142.9
Tmax (h) 24 24
Cmax (ng/mL) 51.8 ± 17.3 35.6 ± 13.0
Css (ng/mL) 37.3 ± 5.34 29.3 ± 6.0
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preliminary data to demonstrate the enhanced transdermal deliv-
ery of donepezil HCl. We have provided ‘proof of concept’ evidence
that donepezil HCl can be delivered in vivo using hydrogel-forming
MNs.
5. Conclusion
This study has demonstrated the in vitro and in vivo delivery of
donepezil HCl via hydrogel forming MNs. This is the first report of
the effective transdermal delivery of donepezil, using a convenient
MN formulation. As the field of MN technology progresses it is
important that due consideration is given to the types of drugs that
will be delivered using this platform. Future work will involve
in vivo sampling beyond 24 h as well as more extensive pharma-
cokinetic analysis to enable progression towards a clinical applica-
tion. By further modification of the MN and/or reservoir patch
formulation, this integrated patch could be optimised to offer a
range of doses over varying time periods. The benefit of transder-
mal products in the treatment of Alzheimer’s disease is well docu-
mented and this study offers substantial promise in the attainment
of a donepezil patch.
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